Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Effect of platelet mediator concentrate (PMC) on Achilles tenocytes: an in vitro study

Fig. 1

Concentrations of growth factors in PMC, serum and plasma. In PMC and serum the PDGF-BB concentration was substantially elevated compared to plasma (3767 ± 593 pg/ml and 1715 ± 399 pg/ml compared to 283 ± 55.8 pg/ml, n = 7, p < 0.05 ). The concentrations of VEGF, TGF-ß and BMP-4 were likewise increased in PMC and serum (VEGF: 464 ± 82.3 pg/ml and 185 ± 20.5 pg/ml to 185 ± 20.5 pg/ml, n = 14; TGF-β: 3022 ± 304 pg/ml and 1936 ± 192 pg/ml to 515 ± 45.8, n = 7; BMP-4: 230 ± 48.9 pg/ml and 147 ± 11.7 pg/ml to 77.7 ± 9.58, n = 9, respectively, p < 0.05). No significant differences were measured between BMP-2 and BMP-7 levels in PMC, serum, or plasma (BMP-2: 77.7 ± 9.58 pg/ml, 943 ± 290 pg/ml and 943 ± 290; respectively; BMP-7: 3059 ± 272 pg/ml, 3059 ± 272 pg/ml and 2577 ± 670 pg/ml; respectively, n = 6, p < 0.05). The levels of both inflammatory cytokine IL-6 and TNF-α were significantly increased in serum as compared to PMC and plasma (IL-6: 1340 ± 242 pg/ml to 177 ± 28.3 pg/ml and 365 ± 64.4 pg/ml, respectively; TNF-α: 2321 ± 362 pg/ml to 413 ± 37.9 pg/ml and 695 ± 44.1 pg/ml, respectively, n = 6, p < 0.05)

Back to article page